This is an expired activity. It is no longer avaialble for credit.

Release Date:    Friday, May 23, 2014

Expiration Date:    Friday, May 22, 2015
Estimated Time To Complete Activity:    1 hour, 15 minutes

AXIS Medical Education invites you to participate in this CME/CE-certified online activity entitled, ”Translating ASH Updates into Clinical Practice: A Video Viewpoint Discussion".
Should you have any questions regarding educational credit for participating in this activity, please contact Postgraduate Institute for Medicine.

Target Audience
This activity has been designed to meet the educational needs of medical oncologists, hematologists, oncology nurses and other oncology healthcare professionals involved with the treatment of cancer.

Activity Overview
An overwhelming amount of new data is presented during the ASH Annual Meeting, highlighting the need to provide oncology and hematology healthcare professionals with access to the latest advances. It is imperative for these healthcare professionals to understand the wide range of therapeutic approaches and newer advances in the treatment of hematologic malignancies in order to optimize patient outcomes. The proposed Video Viewpoints (V2) activity seeks to meet these educational needs and bridge existing knowledge and performance gaps by addressing the most recent clinical advances in hematologic malignancies presented at the 2013 ASH Annual Meeting, and the relevance and integration of this new data to current practice to improve patient outcomes.

Learning Objectives
After completing this activity, the participant should be better able to:

  • Identify emerging evidence reported at ASH 2013 with novel therapies on the horizon for the treatment of hematologic malignancies
  • Evaluate the safety, efficacy and tolerability data from recent and ongoing clinical trials reported at ASH 2013
  • Assess the implications of novel and emerging agents reported at ASH 2013 on clinical practice for the treatment of hematologic malignancies
  • Provide appropriate care and counsel for patients and their families

There is no fee for this educational activity.

Jointly sponsored/co-provided by

This activity is supported by an educational grant from Genentech.